How is the price of selumetinib expected to change in 2025?

Selumetinib As an innovative drug targeting the MEK pathway, its price has always been the focus of widespread concern among patients and the market. Especially after the drug is officially approved in China and included in the medical insurance catalog in 2023, its domestic market price, medical insurance reimbursement ratio and accessibility of generic drugs have become important issues discussed by many parties.

First of all, judging from the current price, the selling price of the original drug of selumetinib within the scope of domestic medical insurance payment has dropped significantly. Taking the more commonly used specifications 10mg×60 tablets and 25mg×60 tablets as examples, the patient's out-of-pocket payment after medical insurance is reduced to about 10% to 30% of the original price, which greatly reduces the patient's burden. In contrast, before being included in medical insurance, the market price of each box can be as high as 20,000 to 50,000 yuan, especially the European version or the imported version from the United States. The price is higher, subject to exchange rate fluctuations, and the economic burden is obvious.

The future price trend mainly depends on several factors: First, the popularity of generic drugs. At present, many pharmaceutical companies in Laos, India and other countries have produced generic versions of selumetinib, and their prices are much lower than the original drug, about 1,000 to 3,000 yuan. As China gradually liberalizes the approval of imported generic drugs and optimizes cross-border e-commerce drug supervision, these generic drugs may legally enter the Chinese market through formal channels, further reducing the price of original drugs.

The second is the continued advancement of medical insurance negotiations. The annual update of the reimbursement drug catalog is accompanied by price renegotiations, especially for innovative drugs with orphan drug background like selumetinib. As the patient population expands and the frequency of use increases, the reimbursement bureau’s efforts to negotiate prices will increase, which means that the price of selumetinib still has room to decline in the future.

The third is the progress in the research and development of domestic generic drugs. If local Chinese companies can break through the core technical bottleneck of MEK inhibitors, independently develop equivalent generic drugs, and achieve approval by the National Medical Products Administration (NMPA) for marketing, then prices will further become more rational and even enter the mid- to low-price range.

Reference materials:https://www.koselugo.com